title: Ghrelin and the cardiovascular system.
abstract: Ghrelin is a peptide that was originally isolated from the stomach. It exerts potent growth hormone (GH)-releasing and orexigenic activities. Several studies have highlighted the therapeutic benefits of ghrelin for the treatment of cardiovascular disease. In animal models of chronic heart failure, the administration of ghrelin improved cardiac function and remodeling; these findings were replicated in human patients with heart failure. Moreover, in an animal study, ghrelin administration effectively reduced pulmonary hypertension induced by chronic hypoxia. In addition, repeated administration of ghrelin to cachectic patients with chronic obstructive pulmonary disease had positive effects on overall body function, including muscle wasting, functional capacity and sympathetic activity. The administration of ghrelin early after myocardial infarction (MI) reduced fatal arrhythmia and related mortality. In ghrelin-deficient mice, both exogenous and endogenous ghrelin were protective against fatal arrhythmia and promoted remodeling after MI. Although the mechanisms underlying the effects of ghrelin on the cardiovascular system remain unclear, there are indications that its beneficial effects are mediated through both direct physiological actions, including increased GH levels, improved energy balance and direct actions on cardiovascular cells, and regulation of autonomic nervous system activity. Therefore, ghrelin is a promising novel therapeutic agent for cardiovascular disease.
authors.affiliation: Department of Biochemistry, Suita, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tokudome
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kishimoto
authors.forename: Mikiya
authors.initials: M
authors.lastname: Miyazato
authors.forename: Kenj
authors.initials: K
authors.lastname: Kangawa
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002319:Cardiovascular System; D005753:Gastric Mucosa / Q000378:metabolism; D054439:Ghrelin / Q000096:biosynthesis / Q000502:physiology* / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D009203:Myocardial Infarction / Q000188:drug therapy; D054440:Receptors, Ghrelin / Q000096:biosynthesis; D013564:Sympathetic Nervous System / Q000187:drug effects
chemical_list: D054439:Ghrelin; D054440:Receptors, Ghrelin